AstraZeneca and Aptamer test fibrotic liver delivery vehicles with siRNA
Drug Discovery World
JULY 10, 2024
Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA.
Let's personalize your content